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Abstract
Background: Cinacalcet is used to treat secondary hyperparathyroidism among hemodialysis patients. Large-scale
epidemiologic studies describing patterns of cinacalcet use, effects on parathyroid hormone (PTH), calcium, and
phosphorous levels, and predictors of discontinuation have not been previously reported.
Methods: This retrospective cohort study used a clinical database of a large U.S. dialysis provider (2007–2010)
merged with administrative data from the United States Renal Data System. Among new users of cinacalcet with
Medicare coverage, trends in PTH, calcium, and phosphorus were measured in 30-day intervals following cinacalcet
initiation.
Results: Seventeen thousand seven hundred sixty-three eligible initiators contributed 111,047 30-day follow-up
intervals. Of these, 56 % discontinued cinacalcet by month 4. Of those discontinuing, 76.3 % reinitiated. Mean
values of PTH, calcium, and phosphorus decreased to recommended levels within 4 months following initiation.
Proximal PTH levels <150 pg/mL were associated with discontinuation: HR = 1.23 (95 % CI: 1.12, 1.36), whereas low
calcium (<7.5 mg/dL) was suggestive of an association, HR = 1.09 (95 % CI 0.91, 1.32). Being in the Part D gap
period increased discontinuation risk: HR = 1.09 (95 % CI: 1.03, 1.16). Low-income subsidy status decreased
discontinuation risk: HR = 0.77 (95 % CI 0.69, 0.86). Predictors of reinitiation included low-income subsidy, HR = 1.32
(95 % CI 1.22, 1.43); higher albumin level, HR = 1.23 (95 % CI 1.10, 1.36) and higher calcium level, HR = 1.26 (95 % CI
1.19, 1.33).
Conclusions: Substantial and expected declines in laboratory values occurred following cinacalcet initiation. Early
discontinuation and reinitiation of cinacalcet were common and may have occurred for clinical and economic reasons.
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Background
Secondary hyperparathyroidism (SHPT) among patients
with chronic kidney disease (CKD) results from decreased
active vitamin D and is manifested by low serum calcium
and elevated levels of phosphorus and parathyroid
hormone (PTH) [1, 2]. Treatment options to control
CKD-MBD parameters include modulation of calcium
and phosphorous balance through dietary intake and
dialysis, active vitamin D compounds, and phosphate
binders [3]. The Kidney Disease: Improving Global Out-
comes (KDIGO) guideline recommendations for the opti-
mal range of PTH is two to nine times the assay's upper
limit of normal reference range, with levels not to exceed
approximately 600 pg/mL. Practitioners are also recom-
mended to target the assay reference range for calcium
and phosphorus [4].
Another therapeutic option is cinacalcet (Sensipar®/
Mimpara®, Amgen Inc., Thousand Oaks, CA), a calcimi-
metic agent that directly lowers PTH, and subsequently,
calcium and phosphorus [5, 6]. However, post-marketing
studies in real world settings have found adherence to
cinacalcet to be sporadic, which may limit its effectiveness
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[7–9]. Identifying factors associated with discontinuation
may help healthcare providers better understand and
prevent non-adherence to therapy. Previous studies exam-
ining adherence to cinacalcet have been limited by size, the
inability to identify time-varying covariates, and inaccur-
acies in identifying therapy start and stop dates [7, 10–12].
Using detailed clinical, laboratory, and healthcare
utilization data from a large cohort of patients receiving
hemodialysis, we sought to describe the experience of
patients initiating cinacalcet, including the trajectory of
biochemical parameters following initiation, as well as fac-
tors predicting discontinuation and reinitiation of therapy.
Methods
Data sources
Our study used 4 years of data (January 1, 2007 through
December 31, 2010) from the United States Renal Data
System (USRDS) linked to data from a large dialysis pro-
vider. The dialysis provider owns and manages over 1,500
outpatient dialysis facilities located throughout the U.S. in
urban, rural, and suburban areas. Their clinical database
captures detailed clinical, laboratory, and treatment data
on patients receiving care at all of their dialysis units. Data
are collected using standardized clinical protocols and
electronic record systems. The USRDS is a national data
system, funded by the National Institute of Diabetes and
Digestive and Kidney Diseases, which collects, analyzes,
and distributes information about the treatment of end-
stage renal disease (ESRD). The USRDS data include data
from the Medical Evidence Report Form, Medicare Enroll-
ment database, ESRD Death Notification Form, as well as
standard analytic files that contain final action claims for
Medicare Parts A, B, and D services [13]. Medicare Parts
A through D are government provided insurance pro-
grams for the elderly, disabled, and those with certain
medical conditions. Permission to use USRDS data was
obtained from The National Institute of Diabetes and
Digestive Kidney Diseases. These data were used to obtain
information on demographic and comorbid characteristics
and health care utilization, such as hospitalizations and
outpatient care.
Study design
Our study used a retrospective new-user cohort design
[14]. Patients were eligible to be included in our study if
they were 18 years and older, had one year of continuous
Medicare Parts A, B, and D coverage during the study
period, and had in-center hemodialysis at the large dialy-
sis provider’s facility. During a 6-month baseline period,
we identified potential confounders and effect modifiers.
Among all eligible patients, new cinacalcet users were
defined as patients who filled at least one 30-day cinacal-
cet prescription without use in the prior 6 months (base-
line period) based on USRDS Medicare Part D claims
files. New users were also required to have received
hemodialysis for at least 9 months and had at least 9
dialysis sessions during the last month of the baseline
period. Patients receiving a parathyroidectomy during the
baseline period or 1st 30-day fill of cinacalcet were ex-
cluded. The cohort construction is outlined in Additional
file 1: Figure S1.
The start of follow-up was on day 31 following an ini-
tial 30-day fill of any dose of cinacalcet. At the end of
each 30-day interval, the patient’s treatment status was
determined. Patients were defined as discontinuing cina-
calcet if there was greater than a 30-day gap from their
last pill day, calculated from the days supply dispensed.
Patients were then followed from discontinuation until
first reinitiation of cinacalcet. Because we did not know
the exact date of discontinuation or reinitiation in a given
interval, the 30-day interval prior to the discontinuation or
reinitiation interval was used for the identification of time-
varying covariates including laboratory values, cardiovascu-
lar and renal risk factors, and medications. The most recent
laboratory or covariate information in the 30-day interval
prior to discontinuation or reinitiation was documented. If
laboratory information was not available in the 30-day
interval, the most recent value in the prior 90 days was doc-
umented. Study schemata are provided in Additional file 1:
Figures S2 and S3. In addition, changes in quintile distribu-
tions of PTH, calcium, and phosphorus were examined
over time in order to assess how increases and decreases
between quintiles predict discontinuation and reinitiation.
A sensitivity analysis was performed to determine if reini-
tiation results were modified when biochemical results
from 5, 7, and 14 days prior to the date of the laboratory
value most proximal to reinitiation were used to predict
reinitiation. This lag time could account for any delays be-
tween physician recognition of a laboratory abnormality
and a decision to reinitiate cinacalcet.
Study variables
Outcomes
Our outcomes of interest were PTH, calcium, and phos-
phorus serum laboratory values measured monthly fol-
lowing cinacalcet initiation and discontinuation, as well
as those leading up to reinitiation of cinacalcet.
Covariates
Descriptions and definitions of baseline and time-varying
covariates are provided in Additional file 1: Table S1 and
Table S2. We identified from Medicare and linked clinical
data demographic, laboratory, and clinical variables, as
well as comorbidities. Covariates included demographic
characteristics (e.g., age, sex, race, Medicaid eligibility,
census region, year), clinical characteristics (e.g., cause of
ESRD, time on dialysis, body mass index, type of vascu-
lar access, number of hospital days), baseline laboratory
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variables (e.g., PTH, calcium, phosphorus), time-varying
laboratory variables divided into categories consistent with
recognized normal and abnormal values, and several time-
varying comorbidity measures. International Classification
of Diseases Ninth Revision codes, Current Procedural
Terminology codes, and Healthcare Common Procedure
Coding System codes were used to identify comorbidities
and procedures.
Statistical analysis
To describe the treatment groups, we report means and
frequencies of all covariates within each treatment group
and subgroups of interest. Trends in means for each lab
value were plotted for the months after initiation and
discontinuation. These plots were smoothed and 95 %
confidence intervals computed using smoothing splines.
For each 30-day interval, we fit a logistic model and esti-
mated the probability of discontinuation or reinitiation
given the most recent time-varying covariates in the 90 days
prior to the 30-day interval in which discontinuation or
reinitiation was thought to have occurred. Although each
patient could contribute multiple 30-day intervals to the
analytic dataset, we did not adjust for repeated measures
since each patient, per our study design, can only dis-
continue once. Patients were censored administratively
on December 31, 2010, and for loss to follow-up, trans-
plant, discontinuation of hemodialysis, death, parathyroid-
ectomy, or loss of Medicare Parts A, B, or D coverage. We
also described trends in biochemical parameters following
treatment discontinuation and leading up to reinitiation
across a range of a priori identified subgroups, including
those defined by age, time on dialysis, and race.
This research was determined to be exempt from review
by the UNC Institutional Review Board. All statistical ana-
lyses were conducted using the R Statistical Software ver-
sion 3.3 [15] and SAS software, Version 9.3, SAS Institute
Inc., Cary, NC, USA.
Results
We identified 17,763 patients who met our study entry
requirements and contributed 111,047 30-day follow-up
intervals. Table 1 presents patient characteristics of the
primary cohort stratified by gender. All covariates con-
sidered can be found in Additional file 1: Table S3. At
cinacalcet initiation, the average age was 56.7 years (stand-
ard deviation (SD) 14.5 years) and the average time on
dialysis was 4.5 years (SD 4.3 years), 49.3 % of the cohort
was female, and 53.8 % were African American. Several
baseline financial factors were also identified. A history of
receiving Medicaid benefits or having low-income subsidy
was identified in 68.7 and 83.9 %, respectively. Mean PTH
calcium, and phosphorus at initiation were 642 pg/mL
(SD 519 pg/mL), 9.4 mg/dL (SD 0.7 mg/dL), and 5.9 mg/
dL (SD 1.7 mg/dL), respectively.
Trends in the mean serum lab values of PTH, calcium,
and phosphorus for the first 12 months following cina-
calcet initiation, as well as after discontinuation, are
shown in Figs. 1, 2 and 3. Following cinacalcet initiation,
the levels of the three lab values fell and stabilized at ap-
proximately month 4. Mean PTH levels decreased from
a baseline level of 642 pg/mL (SD 519 pg/mL) to levels
between 375 and 400 pg/mL in months 4 through 12.
Mean calcium levels decreased from a baseline level of
9.4 mg/dL (SD 0.7 mg/dL) to approximately 8.9 mg/dL
during the 1st month and remained at levels slightly
higher than 8.9 mg/dL between months 4 through 12.
Of the 111,047 30-day intervals examined, 17,980 inter-
vals (16.7 %) had a PTH level less than 150 pg/mL and
1,934 (1.8 %) had a calcium level less than 7.5 mg/dL,
Additional file 1: Table S4. Phosphorus levels decreased
from a baseline mean level of 5.9 mg/dL (SD 1.7 mg/dL)
to between 5.2 and 5.4 mg/dL in months 4 through 12.
Following discontinuation, mean levels of PTH, calcium,
and phosphorus increased and then stabilized at higher
mean levels than those achieved while on therapy.
The probability of discontinuation by month 4 was 56 %
and by month 12 was 73 %. Of those who discontinued
(N = 12,521), 76.3 % (N = 9,558) reinitiated cinacalcet. The
mean time to reinitiation was 4.0 months. Predictors of
cinacalcet discontinuation and reinitiation are presented
in Table 2. All covariates considered can be found in
Additional file 1: Table S5. Baseline PTH, calcium, and
phosphorus serum levels were not associated with dis-
continuation; however, levels most proximal to discon-
tinuation were. Low proximal levels of PTH (<150 pg/mL)
were associated with discontinuation, HR 1.23 (95 % CI
1.12, 1.36). There was a slight association between calcium
(<7.5 mg/dL) and discontinuation, HR 1.09 (95 % CI 0.91,
1.32). Increasing levels of PTH and calcium over time,
based on changes in quintile distributions, were also asso-
ciated with discontinuation, HR 1.15 (95 % CI 1.07, 1.23)
and HR 1.24 (95 % CI 1.16, 1.32), respectively. The dose of
cinacalcet most proximal to discontinuation also predicted
discontinuation in this population. Compared to 30 mg, a
recent dose of 60 mg of cinacalcet slightly predicted dis-
continuation, HR 1.07 (95 % CI 1.00, 1.15), while a recent
dose of 90 mg compared to 30 mg had a stronger associ-
ation, HR 1.15 (95 % CI 1.03, 1.29). Other factors associ-
ated with discontinuation included increasing copay, in
the follow-up period, HR 1.04 (95 % CI 1.02, 1.07); time
spent in the hospital, HR 2.02 (95 % CI 1.84, 2.22); being
in the Medicare Part D gap period, HR 1.09 (95 % CI 1.03,
1.16); and a diagnosis of stroke during follow-up, HR 1.30
(95 % CI 1.06, 1.60). Nausea, vomiting, and diarrhea were
not common in our study given the limitation of ICD-9
diagnosis codes to identify these outcomes, N = 1,308 30-
day intervals (1.2 %) and were only slightly predictive of
discontinuation, HR 1.09 (95 % CI 0.91, 1.32). Proximal
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Table 1 Baseline characteristics overall and by gender
Characteristica Total Female Male
Demographics
Patients, N 17,763 8,764 8,999
Age, mean (SD), yearsb 56.7 (14.5) 59.1 (14.8) 54.4 (13.9)
Time on dialysis, mean (SD), yearsb 4.5 (4.3) 4.4 (4.1) 4.7 (4.4)
Race, N (%)
White 7,242 (40.8) 3,436 (39.2) 3,806 (42.3)
African American 9,555 (53.8) 4,856 (55.4) 4,699 (52.2)
Other Race 966 (5.4) 472 (5.4) 494 (5.5)
Cause of ESRD, N (%)
Diabetes 7,629 (42.9) 4,233 (48.3) 3,396 (37.7)
Hypertension 5,612 (31.6) 2,458 (28.0) 3,154 (35.0)
Glomerulonephritis 2,236 (12.6) 1,067 (12.2) 1,169 (13.0)
Other 2,286 (12.9) 1,006 (11.5) 1,280 (14.2)
Body Mass Index, mean (SD), kg/m2 28.0 (7.3) 28.7 (7.8) 27.4 (6.7)
Financial Considerations
Medicaid, N (%) 12,206 (68.7) 6,351 (72.5) 5,855 (65.1)
Low-income subsidy, N (%) 14,906 (83.9) 7,515 (85.7) 7,391 (82.1)
Concomitant medications, N (%)c 4.7 (3.6) 5.1 (3.7) 4.4 (3.5)
Biochemical Values
Albumin, mean (SD), g/dLd 3.9 (0.4) 3.8 (0.4) 4.0 (0.4)
Calcium, mean (SD), mg/dLd 9.4 (0.7) 9.4 (0.7) 9.4 (0.7)
Phosphorus, mean (SD), mg/dLd 5.9 (1.7) 5.8 (1.7) 6.0 (1.7)
Parathyroid hormone, mean (SD), pg/mLd 642 (519) 640 (519) 644 (520)
Comorbidities
Congestive heart failure, N (%) 4,823 (27.2) 2,592 (29.6) 2,231 (24.8)
Coronary artery disease/atherosclerosis, N (%) 4,703 (26.5) 2,434 (27.8) 2,269 (25.2)
Cerebrovascular disease, N (%) 1,891 (10.6) 1,087 (12.4) 804 (8.9)
Hypertension, N (%) 12,393 (69.8) 6,481 (74.0) 5,912 (65.7)
Peripheral vascular disease, N (%) 2,352 (13.2) 1,208 (13.8) 1,144 (12.7)
Hyperlipidemia, N (%) 4,658 (26.2) 2,519 (28.7) 2,139 (23.8)
Chronic obstructive pulmonary disease or asthma, N (%) 2,727 (15.4) 1,530 (17.5) 1,197 (13.3)
Diabetes, N (%) 10,052 (56.6) 5,491 (62.7) 4,561 (50.7)
Dialysis Care
Phosphorus binder drug, N (%)e 14,135 (79.6) 7,037 (80.3) 7,098 (78.9)
Catheter access, N (%) 3,351 (18.9) 1,994 (22.8) 1,357 (15.1)
Mean intravenous vitamin D dosage, micrograms (SD)f 12.5 (10.3) 11.9 (9.9) 13.1 (10.7)
Note: Conversion factors for units: Calcium in mg/dL to mmol/L, x0.2495; phosphorus in mg/dL to mmol/L, x0.3229
aCharacteristics were identified using information from Medicare Part A or B claims. A characteristic was considered present if at least one inpatient, home health,
or skilled nursing facility claim, or at least two outpatient or physician/supplier claims separated by at least 7 days, were identified during the 6-month baseline
period. Additional information concerning covariates can be found in Additional file 1: Table S3
bAge and time on dialysis are at the time of cinacalcet initiation
cConcomitant medications are the number of concomitant medications at the time of cinacalcet initiation
dLaboratory values were those most proximal to the index date during the baseline period
ePhosphate binders included in the analysis: Sevelamer hydrochloride, sevelamer carbonate, lanthanum carbonate, and calcium acetate
fMean intravenous vitamin D dose per person in the last month of the baseline period. Paricalcitol and doxercalciferol doses were converted to calcitriol-
equivalent doses according to the following conversion ratios: 4.6: 1 for paricalcitol: calcitriol and 3.1: 1 for doxercalciferol: calcitriol
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PTH values in all categories examined did not predict
reinitiation of cinacalcet. Both increasing and decreasing
levels of PTH over time, based on changes in quintile dis-
tributions, were both associated with reinitiation of PTH,
HR 1.08 (95 % CI 1.03, 1.14) and HR 1.12 (95 % CI 1.06,
1.19), respectively. Proximal calcium levels both lower and
higher were predictive of cinacalcet reinitiation; however,
the results of the sensitivity analysis, which used the cal-
cium value 14 days prior to the date of the laboratory
value most proximal to reinitiation, showed that only
higher calcium levels were associated with reinitiation, HR
1.26 (95 % CI 1.19, 1.33), Additional file 1: Table S6. All
other sensitivity analysis results were not greatly changed
when prior laboratory values were used to predict reinitia-
tion. Other predictors of reinitiation included low-income
subsidy, HR = 1.32 (95 % CI 1.22, 1.43), African American
race, HR = 1.08 (95 % CI 1.03, 1.13), and higher albumin
level, HR = 1.23 (95 % CI 1.10, 1.36).
Discussion
In a cohort of contemporary hemodialysis patients, we
observed the effectiveness of cinacalcet in lowering levels
of PTH, calcium, and phosphorus, and determined predic-
tors of early cinacalcet discontinuation and subsequent re-
initiation. The reductions in these lab values are observed
soon after initiation of cinacalcet and mean levels of PTH,
calcium, and phosphorus appear to be sustained within
recommended target ranges. Yet, discontinuation occurs
frequently and relatively soon after initiation of cinacalcet
treatment, on average within 4 months following initiation,
Additional file 1: Table S7. Furthermore, discontinuation in
this population resulted in the loss of biochemical control.
Several variables predicted discontinuation. Some of these
variables were biochemical, including declining PTH and
calcium levels, and others were related to drug prescription
drug coverage and novel findings associated with changes
in health status. Variables predicting reinitiation were
generally similar to those predicting discontinuation.
Average PTH, calcium, and phosphorus levels following
cinacalcet initiation in our study were consistent with the
2009 KDIGO guideline update, despite a portion of the
follow-up period occurring prior to the release of the
guidelines [4]. These guidelines suggest a PTH level in the
range of approximately 2 to 9 times the upper reference
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Fig. 1 Mean PTH levels and 95 % confidence intervals by month following cinacalcet initiation and discontinuation
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limit for the assay, which corresponds to approximately
130 to 600 pg/mL, taking into account variability in
commercial assays. In our study, average serum calcium
levels were maintained in the reference range, in which
the recommended upper level of the range is 10.0 mg/dL
to 10.5 mg/dL, depending on the assay used. Average
phosphorus levels in our study decreased toward the refer-
ence range, which is 2.4 to 4.1 mg/dL, differing slightly
among assays. For patients who remained on cinacalcet,
biochemical control persisted for up to one year of
follow-up. Our results are also similar to those from a
recent retrospective cohort study that showed decreases in
all three biochemistries that were sustained for 1-year fol-
lowing cinacalcet initiation, although we did not assess
dose-titration and its impact on control [7]. Following dis-
continuation of cinacalcet in the current study, biochemical
values increased quickly then leveled off or decreased
slightly, Figs. 1, 2 and 3. The slight decreases in biochemical
levels are likely due to a selection effect that would result
from patients with higher levels restarting treatment and
thus being censored from the analysis. Similar to a prior
study [16], vitamin D doses in our population decreased
following cinacalcet initiation and increased following cina-
calcet discontinuation, Additional file 1: Figure S4.
Despite evidence of improved control of SHPT-related
biochemical parameters, discontinuation of cinacalcet was
common, with 56 % discontinuing by month 4 and 73 %
discontinuing by month 12. This rate of discontinuation is
greater than what has been reported in previous cinacalcet
studies. Although we cannot know the precise cause of dis-
continuation, our study is the first to include a large sample
size and verify use through Medicare Part D prescription
claims, which overcomes many of the possible inaccuracies
in start and stop dates [7, 10–12]. Prior studies of medica-
tion adherence in the general and CKD populations have
found that >50 % of patients demonstrate poor adherence
to chronic medications [17]. While poor patient adherence
is possible in our population, reinitiation in our population
was common and on average occurred 4 months after
the first discontinuation. These findings suggest that
discontinuation is due to several factors and likely to
encompass both patient-initiated (non-adherence) and
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Fig. 2 Mean calcium levels and 95 % confidence intervals by month following cinacalcet initiation and discontinuation. Note: Conversion factors
for units: Calcium in mg/dL to mmol/L, x0.2495
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physician-initiated, medically driven (biochemical value
influences) factors.
Our study identified possible predictors that may illumin-
ate why certain patients are discontinued from cinacalcet.
While the prescribing information for cinacalcet indicates
that administration should be withheld if serum calcium
falls below 7.5 mg/dL, only a small proportion of patients
experienced hypocalcemia and the modeling revealed it as
a weak predictor of discontinuation. PTH levels falling
below 150 pg/mL was more common and was predictive of
discontinuation, consistent with prescribing information.
Higher doses of cinacalcet at the time of discontinuation
also predicted discontinuation, which may further illustrate
the role of low or at goal laboratory values in the decision
to discontinue cinacalcet. Other possible cinacalcet side ef-
fects, nausea, vomiting, and diarrhea [18], were also not
common in our study, but did have a weak association with
discontinuation. However, because nausea and vomiting are
likely to be under reported, measuring this well-recognized
side effect is difficult and definitive conclusions from the
observed results cannot be drawn for this variable.
We also identified factors related to medication cost
that were predictive of discontinuation and reinitiation,
suggesting that financial issues could play a role in pa-
tients’ decisions to discontinue and reinitiate treatment.
Patients identified as ever having low-income subsidy
status, indicating a lower-out-of pocket cost for cinacalcet,
were less likely to discontinue and more likely to reinitiate
therapy following discontinuation. Entering the Medicare
Part D gap period or being in the Medicare Part D gap
period, when out-of-pocket costs are significant, increased
the risk of discontinuation. Increasing copay during follow-
up also slightly increased the risk of discontinuation. Our
results are similar to the findings of a recent study of adher-
ence and persistence of oral medications, defined as ≥ 80 %
medication possession ratio and duration of use, among
Medicare Part D beneficiaries receiving dialysis [19]. The
investigators found patients not receiving the low-income
subsidy and patients entering into the coverage gap were
more likely to be non-adherent and had less persistent use
of cinacalcet [19]. The investigators found similar relation-
ships with other oral medications indicating that the impact
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factors for units: phosphorus in mg/dL to mmol/L, x0.3229
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Table 2 Predictors of discontinuation and reinitiation
Characteristica Discontinuation (HR, 95 % CI) Reinitiation (HR, 95 % CI)
Number of time intervals for analysis, N (%) 100,706 (90.7 %) 78,789 (96.0 %)
Demographics
Age, years, reference 46-55
≤45 0.92 (0.85, 1.00) 0.95 (0.90, 1.02)
56-65 1.05 (0.97, 1.13) 0.98 (0.92, 1.04)
66-75 1.05 (0.97, 1.15) 0.90 (0.85, 0.97)
≥75 0.98 (0.88, 1.09) 0.95 (0.87, 1.04)
Time on dialysis, years, reference <1
1-3 1.15 (1.01, 1.30) 1.00 (0.91, 1.11)
≥4 1.14 (1.00, 1.30) 1.03 (0.92, 1.14)
Female 1.07 (1.01, 1.13) 1.00 (0.96, 1.05)
African American 1.04 (0.98, 1.10) 1.08 (1.03, 1.13)
Cause of ESRD, reference diabetes mellitus
Hypertension 1.02 (0.94, 1.10) 1.04 (0.98, 1.11)
Glomerulonephritis 1.01 (0.90, 1.12) 1.08 (0.99, 1.17)
Other 0.96 (0.87, 1.06) 1.03 (0.95, 1.12)
Body mass index, kg/m2, reference normal
Underweight 1.07 (0.93, 1.23) 0.98 (0.87, 1.10)
Overweight 1.03 (0.96, 1.10) 1.03 (0.98, 1.09)
Obese 0.98 (0.91, 1.04) 1.11 (1.05, 1.17)
Financial considerations
Medicaid 1.03 (0.96, 1.11) 0.96 (0.91, 1.02)
Low-income subsidy 0.76 (0.68, 0.85) 1.32 (1.22, 1.43)
Concomitant medications in baseline periodb 0.98 (0.97, 0.99) 1.00 (0.99, 1.01)
Concomitant medications in follow-up periodb 0.96 (0.95, 0.97) 0.98 (0.97, 0.99)
Copay in follow-up periodc 1.04 (1.01, 1.06) 1.04 (1.02, 1.06)
Last benefit phase in follow-up, reference: coveredd
Entering the gap period 1.19 (1.00, 1.41) 1.01 (0.85, 1.21)
Exiting or going through gap period 0.98 (0.77, 1.23) 1.03 (0.81, 1.32)
In the gap period 1.10 (1.04, 1.16) 1.01 (0.96, 1.06)
Biochemical values
Albumin in baseline period, reference: <3.3 g/dL
3.3-3.9 g/dL 1.11 (0.97, 1.28) 1.13 (1.00, 1.27)
>3.9 g/dL 1.05 (0.91, 1.21) 1.09 (0.96, 1.23)
Albumin in follow-up period, reference: <3.3 g/dL
3.3-3.9 g/dL 0.85 (0.76, 0.95) 1.13 (1.02, 1.25)
>3.9 g/dL 0.78 (0.69, 0.88) 1.23 (1.10, 1.36)
Phosphorus in baseline period, mg/dL 1.02 (1.00, 1.04) 0.98 (0.96, 0.99)
Phosphorus in follow-up period, mg/dL 1.02 (1.00, 1.04) 0.99 (0.98, 1.01)
Parathyroid hormone in baseline period, pg/mLe 1.00 (0.99, 1.01) 1.00 (0.99, 1.00)
Parathyroid hormone in follow-up period, reference: >600 pg/mL
<150 pg/mL 1.24 (1.12, 1.37) 0.70 (0.64, 0.76)
150-300 pg/mL 0.91 (0.83, 0.99) 0.71 (0.66, 0.75)
301-600 pg/mL 0.89 (0.82, 0.97) 0.85 (0.80, 0.90)
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Table 2 Predictors of discontinuation and reinitiation (Continued)
Parathyroid hormone in follow-up period, change in quintiles, reference: no changef
Increase 1.15 (1.07, 1.23) 1.08 (1.03, 1.14)
Decrease 0.90 (0.84, 0.97) 1.12 (1.06, 1.19)
Calcium in baseline period, mg/dL 0.95 (0.91, 0.99) 1.16 (1.12, 1.20)
Calcium in follow-up period, reference: >8.7 mg/dLg
<7.5 mg/dL 1.07 (0.89, 1.29) 1.12 (0.91, 1.39)
7.5-8.7 mg/dL 0.85 (0.80, 0.91) 1.26 (1.19, 1.33)
Calcium in follow-up period, change in quintiles, reference: no changef
Increase 1.24 (1.16, 1.32) 1.07 (1.02, 1.13)
Decrease 0.94 (0.88, 1.00) 1.04 (0.99, 1.10)
Comorbidities
Congestive heart failure in baseline period 1.06 (0.99, 1.13) 0.96 (0.91, 1.01)
Congestive heart failure in follow-up period 1.01 (0.90, 1.14) 1.11 (0.94, 1.31)
Coronary artery disease/atherosclerosis in baseline period 1.01 (0.95, 1.09) 0.93 (0.88, 0.99)
Cerebrovascular disease in baseline period 0.94 (0.86, 1.02) 1.00 (0.93, 1.07)
Stroke in follow-up period 1.30 (1.05, 1.60) 0.82 (0.55, 1.20)
Hypertension in baseline period 1.12 (1.05, 1.19) 1.03 (0.98, 1.08)
Peripheral vascular disease in baseline period 1.02 (0.94, 1.11) 1.11 (1.03, 1.19)
Peripheral vascular disease in follow-up period 0.99 (0.85, 1.16) 0.91 (0.76, 1.09)
Hyperlipidemia in baseline period 1.01 (0.95, 1.07) 1.06 (1.01, 1.12)
Chronic obstructive pulmonary disease and asthma in baseline period 1.00 (0.93, 1.08) 1.00 (0.94, 1.06)
Diabetes in baseline period 1.05 (0.98, 1.14) 0.98 (0.92, 1.04)
Nausea, vomiting, diarrhea in follow-up period 1.09 (0.91, 1.32) 1.05 (0.85, 1.31)
Seizure in follow-up period 1.18 (0.93, 1.49) 1.11 (0.82, 1.50)
Dialysis care
Intravenous vitamin D in baseline periodh 1.01 (0.98, 1.05) 0.98 (0.96, 1.00)
Intravenous vitamin D in follow-up periodh 0.94 (0.91, 0.97) 1.02 (0.99, 1.04)
Phosphorus binder drug in baseline periodi 1.02 (0.95, 1.10) 1.12 (1.06, 1.18)
Phosphorus binder drug in follow-up periodi 0.77 (0.73, 0.82) 1.03 (0.98, 1.08)
Catheter access in baseline period 0.97 (0.89, 1.07) 1.07 (0.99, 1.15)
Catheter access in follow-up period 1.10 (1.00, 1.21) 0.83 (0.77, 0.90)
Most recent dose of cinacalcet, reference: 30 mg
60 mg 1.07 (1.00, 1.15) n/a
90 mg 1.15 (1.03, 1.29) n/a
Days in the hospital in follow-up period, reference: 0 days
1-4 days 2.02 (1.84, 2.22) 0.85 (0.75, 0.96)
≥5 days 1.90 (1.73, 2.08) 0.79 (0.69, 0.89)
Note: Conversion factors for units: Calcium in mg/dL to mmol/L, x0.2495; phosphorus in mg/dL to mmol/L, x0.3229
aBaseline characteristics were identified using information from Medicare Part A or B claims. A characteristic was considered present if at least one inpatient,
home health, or skilled nursing facility claim, or at least two outpatient or physician/supplier claims separated by at least 7 days, were identified during the
6-month baseline period. Additional information concerning baseline characteristics can be found in Additional file 1: Table S4. Time-varying (follow-up) characteristics
were evaluated at 30-day intervals following the start of follow-up. Additional information concerning time-varying (follow-up) characteristics can be found in Additional
file 1: Table S2
bConcomitant medications are the number of concomitant medications at the time of cinacalcet discontinuation or reinitiation
cChanges in co-pay were based on increments of $100. The last co-pay prior to discontinuation was used to predict cinacalcet reinitiation
dBenefit phase reflects the status of Medicare Part D coverage at the time of the fill of cinacalcet
eChanges in parathyroid hormone level were based on increments of 100 pg/mL
fDistributions of parathyroid hormone and calcium were examined across all of follow-up and quintiles were based on these distributions. Increase indicates an
increase to another quintile and trend of increasing laboratory levels. Decrease indicates a decrease to another quintile and a trend of decreasing laboratory levels
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of economic burden in this population is not specific to
cinacalcet. Therapy regimens for patients receiving dialysis
are burdensome, and patients are prescribed on average
10–12 tablets per day, all likely leading to financial burden
[10, 20, 21].
It has been recommended that therapeutic decisions
in CKD patients be based on trends, rather than single
laboratory values [4]. Therefore, in addition to examin-
ing the laboratory values most proximal to the time of
discontinuation, we also examined the changes in lab
values leading up to discontinuation. Our most striking
finding was that trends of increasing levels of PTH and
calcium over time were associated with discontinuation.
This finding could be an early signal of non-adherence.
As patients become non-adherent to cinacalcet due to
side effects, financial issues, or medication complexity,
rising levels of PTH and calcium could be apparent and
a signal to clinicians to consider that factors other than
medication ineffectiveness may be an issue. Identifying
ways to decrease medication complexity, financial burdens,
and side effects could enable patients to persist longer on
cinacalcet therapy.
Several limitations of our study must be noted. First,
medication use information was obtained from phar-
macy claims, which are an imperfect measure of actual
medication consumed. It is possible that patients were
obtaining medications outside of their Medicare Part D
benefit [22, 23]. We also cannot precisely determine the
day when patients stops or reinitiates treatment. However,
we adopted a design to minimize the likelihood that
predictors would be assessed following discontinuation
or reinitiation events, thus avoiding the problem of pre-
dictors being consequences of discontinuation or reini-
tiation, rather than causes. In addition, we performed a
sensitivity analysis to determine if a delay in physician
recognition and response to a laboratory value could
affect reinitiation results. Adding a lag in the dates of
the biochemical values affected calcium reinitiation re-
sults, a biochemical test drawn frequently, but not PTH
results, a biochemical test drawn less frequently. In fu-
ture studies using claims data, consideration of the
time frame of when frequent biochemical values are
drawn and when a physician would realistically identify
and act on a biochemical value should be considered.
Finally, many of our variables were assessed using ICD-
9 codes associated with health care encounters. Many
of these definitions, such as those for acute myocardial
infarction [24], are known to have very high sensitivity
and specificity, but others, such as those for nausea, are
likely to be much less sensitive.
Conclusions
The results of our study indicate that on average biochem-
ical control of PTH, calcium, and phosphorus following
cinacalcet initiation were consistent with recommendations
in the 2009 KDIGO guideline update. Yet, early discon-
tinuation of cinacalcet was frequent and resulted in the
loss of control of PTH, calcium, and phosphorus. Both
economic and clinical factors contribute to cinacalcet
discontinuation, as well as reinitiation. Examining trends in
laboratory values over time could identify early signals of
non-adherence and present an opportunity for clinicians to
intervene. In conclusion, prolonged biochemical control
was achieved by continued cinacalcet therapy and factors
associated with discontinuation and reinitiation indicate
persistent use of and adherence to cinacalcet are impacted
by a range of both modifiable and immutable factors.
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